Knobbe Martens Olson & Bear LLP
San Diego
Biotechnology and pharmaceuticals
There's been a decline in new biotechnology startups due to a dropoff in available capital, but Israelsen's existing clients continue to generate cash and protect the intellectual property that makes them attractive to investors.
"Fortunately, my clients have managed to find new investments and keep going...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In